18
Mar

Orphan drug biotech Retrophin is the new owner of an FDA-approved rare disease treatment and a potentially lucrative voucher for a future speedy review thanks to a $75 million buyout agreement.

…read more

Source: Retrophin bags rare disease approval, FDA voucher in $75M deal

    

0 No comments